Key result
Aspirin plus extended-release dipyridamole resulted in similar rates of recurrent stroke compared to clopidogrel but increased the risk of major hemorrhage.
Why the study?
Does aspirin plus extended-release dipyridamole reduce recurrent stroke compared to clopidogrel in patients with recent noncardioembolic ischemic stroke?
RCT (n=20,000)
Yes
Does aspirin plus extended-release dipyridamole reduce recurrent stroke compared to clopidogrel in patients with recent noncardioembolic ischemic stroke?
Answers are grounded in this paper and cite their sources.
Aspirin plus extended-release dipyridamole showed similar efficacy to clopidogrel for preventing recurrent stroke but was associated with higher rates of major hemorrhage and discontinuation due to headache.
R ecently, the results of the Prevention Regimen for EFfectively avoiding Second Strokes trial (PRoFESS) were published after they had been presented at the European Stroke Conference in Nice, May 2008. 1 It was a large multicenter clinical trial among over 20 000 patients with a recent (mainly 3 months) ischemic stroke that was of noncardioembolic origin in virtually all. The trial had 2 treatment contrasts that were studied simultaneously, one on 2 antiplatelet regimens, the other on telmisartan versus placebo. 2 This comment addresses only the comparison of aspirin (25 mg) plus extended-release dipyridamole (200 mg) twice daily (ASA-ERDP) versus clopidogrel (75 mg) once daily. Primary outcome was recurrent stroke and secondary outcome the AntiPlatelet Trialists' composite of vascular death, nonfatal myocardial infarction, or nonfatal stroke. Mean follow-up was 2.5 years. There were 916 recurrent strokes (primary outcome) with ASA-ERDP versus 898 with clopidogrel with a resulting hazard ratio (HR) of 1.01 (95% CI, 0.92 to 1.11). In both groups, there were 1333 vascular events (stroke, myocardial infarction, or vascular death); the HR was 0.99 (95% CI, 0.92 to 1.07) and the corresponding relative risk reduction (RRR) 1% (95% CI, 7% to 8%). In the ASA-ERDP group, there were more major hemorrhages (419) than in the clopidogrel group (365; HR, 1.15; 95% CI, 1.00 to 1.32). There was an excess of 44 intracranial hemorrhages with ASA-ERDP (147) as compared with clopidogrel (103; HR, 1.42; 95% CI, 1.11 to 1.83). For the tertiary outcome "stroke or major hemorrhage," the HR was 1.03 (95% CI, 0.95 to 1.12). Patients on ASA-ERDP more often discontinued their study drug early (29.1%) than patients on clopidogrel (22.6%; 6.5% difference; 95% CI, 5.3% to 7.7%). Headache was the adverse event leading to permanent discontinuation of study drug in 593 patients on ASA-ERDP, whereas this number was 87 for clopidogrel (5.0% difference; 4.5 to 5.5%). The authors conclude that the PRoFESS trial showed similar rates of recurrent stroke and vascular events for the 2 treatment strategies and that the net benefit was similar based on the composite outcome of recurrent stroke or major hemorrhage.
No takes yet. Share an insight, caveat, or question.
Ale Algra (2008) conducted an RCT in Recent ischemic stroke of noncardioembolic origin (n=20,000). Aspirin plus extended-release dipyridamole (ASA-ERDP) vs. Clopidogrel 75 mg once daily was evaluated on Recurrent stroke (HR 1.01, 95% CI 0.92-1.11). Aspirin plus extended-release dipyridamole resulted in similar rates of recurrent stroke compared to clopidogrel but increased the risk of major hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: